EUVIMEDEUVIMED entdecken
Crossref

Enhanced Theranostic Efficacy of 89 Zr and 177 Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice

Zhao Chen iD, Qi Yang, Lele Song, Yongkang Qiu, Tianyao Wang, Sitong Wu, Wenpeng Huang, Xinyao Sun, Aixiang Wang, Lei Kang iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Zhao Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Zirconium, Lutetium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Peking University First Hospital, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular endothelial growth factor (VEGF) targeted therapy serves as an important therapeutic approach for renal cancer, but its clinical effectiveness is unsatisfactory. Moreover, there is a lack of reliable biomarkers for preoperative assessment of tumor VEGF expression. This study aimed to explore the potential for further applications of 177Lu/89Zr-labeled aflibercept (Abe), a VEGF-binding agent, in imaging visualization of VEGF expression and therapy for renal cancer. To determine specificity uptake in renal cancer, BALB/c mice with VEGF-expressing Renca tumor were intravenously injected with [89Zr]Zr-Abe, [177Lu]Lu-Abe, or Cy5.5-Abe and the blocking group was designed as a control group. PET, SPECT, and fluorescence images were acquired, and the biodistribution of [89Zr]Zr-Abe and [177Lu]Lu-Abe was performed. Additionally, the [177Lu]Lu-Abe, [177Lu]Lu-Abe-block, 177Lu only, Abe only, and PBS groups were compared for evaluation of the therapeutic effect. To assess the safety, we monitored and evaluated the body weight, blood biochemistry analysis, and whole blood analysis and major organs were stained with hematoxylin and eosin after [177Lu]Lu-Abe treatment. DOTA-Abe was successfully labeled with 177Lu and Df-Abe with 89Zr in our study. The uptake in tumor of [89Zr]Zr-Abe was significantly higher than that of [89Zr]Zr-Abe-block (P < 0.05) and provided excellent tumor contrast in PET images. [177Lu]Lu-Abe demonstrated promising tumor-specific targeting capability with a high and persistent tumor uptake. The standardized tumor volume of [177Lu]Lu-Abe was significantly smaller than those of other treatment groups (P < 0.05). [177Lu]Lu-Abe also had smaller tumor volumes and reduced expression of VEGF and CD31 compared to those of the control groups. Fluorescence images demonstrate higher tumor uptake in the Cy5.5-Abe group compared to the Cy5.5-Abe-block group (P < 0.05). In conclusion, [89Zr]Zr-Abe enables noninvasive analysis of VEGF expression, serving as a valuable tool for assessing the VEGF-targeted therapy effect. Additionally, all of the findings support the enhanced therapeutic efficacy and safety of [177Lu]Lu-Abe, making it a viable option for clinical practice in renal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsZirconiumLutetiumRadioisotopesKidney NeoplasmsMice, Inbred BALB CAnimalsMiceTissue DistributionHumansCell Line, TumorVascular Endothelial Growth Factor ARadiopharmaceuticalsTheranostic NanomedicineFemalePositron-Emission TomographyXenograft Model Antitumor Assays

Stichwörter der Autor:innen

VEGFZirconium-89afliberceptlutetium-177radioimmunotherapyrenal cancer

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsZirconiumLutetiumRadioisotopesLutetium-177Zirconium-89Vascular Endothelial Growth Factor ARadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
  • Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing 100034, China.
  • Department of Urology, Peking University First Hospital, Beijing 100034, China.
  • Institute of Urology, Peking University, Beijing 100034, China.

ORCID-Profile: Zhao Chen, Lei Kang

Förderung

  • Peking University First Hospital
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
  • National Natural Science Foundation of China
  • Beijing Science Foundation for Distinguished Young Scholars

Zitieren

APA

Chen, Z., Yang, Q., Song, L., Qiu, Y., Wang, T., Wu, S., Huang, W., Sun, X., Wang, A., & Kang, L. (2024). Enhanced Theranostic Efficacy of 89 Zr and 177 Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00084

Vancouver

Chen Z, Yang Q, Song L, Qiu Y, Wang T, Wu S, et al. Enhanced Theranostic Efficacy of 89 Zr and 177 Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00084

BibTeX
@article{Chen2024,
  author = {Chen, Zhao and Yang, Qi and Song, Lele and Qiu, Yongkang and Wang, Tianyao and Wu, Sitong and Huang, Wenpeng and Sun, Xinyao and Wang, Aixiang and Kang, Lei},
  title = {Enhanced Theranostic Efficacy of 89 Zr and 177 Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00084}
}
Kostenlos starten →